Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS

Key Points

• Dimensional Fund Advisors increased its Aclaris Therapeutics stake by 88.8% in the first quarter, adding 240,611 shares to hold 511,461 shares worth approximately $1.91 million. Institutional investors and hedge funds collectively own 98.34% of the stock.
• Analyst sentiment is broadly positive, with an average rating of “Buy” and an average price target of $11.50, compared with the stock’s Friday opening price of $5.86. Price targets ranged from $10 to $13, although one analyst maintained a sell rating.
• Aclaris reported quarterly revenue of $1.63 million and an adjusted loss of $0.15 per share, slightly exceeding analyst expectations. The clinical-stage biotechnology company is developing small-molecule therapies for dermatologic diseases, including treatments for molluscum contagiosum, warts and inflammatory disorders.

Dimensional Fund Advisors LP grew its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 88.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 511,461 shares of the biotechnology company's stock after buying an additional 240,611 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.37% of Aclaris Therapeutics worth $1,914,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of Aclaris Therapeutics by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company's stock valued at $776,000 after acquiring an additional 3,507 shares in the last quarter. Strs Ohio acquired a new position in Aclaris Therapeutics in the 1st quarter worth about $60,000. Assenagon Asset Management S.A. raised its position in Aclaris Therapeutics by 14.7% in the first quarter. Assenagon Asset Management S.A. now owns 177,283 shares of the biotechnology company's stock valued at $665,000 after purchasing an additional 22,729 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Aclaris Therapeutics by 73.6% during the first quarter. SG Americas Securities LLC now owns 26,767 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 11,344 shares in the last quarter. Finally, Diversified Trust Co acquired a new stake in shares of Aclaris Therapeutics during the first quarter valued at about $110,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Guggenheim initiated coverage on shares of Aclaris Therapeutics in a report on Tuesday, May 5th. They issued a "buy" rating and a $12.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Aclaris Therapeutics in a report on Wednesday, June 24th. Wall Street Zen raised shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Lifesci Capital assumed coverage on shares of Aclaris Therapeutics in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $13.00 price target on the stock. Finally, Wedbush lifted their price objective on Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 29th. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $11.50.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $5.86 on Friday. The business has a 50-day simple moving average of $5.24 and a 200 day simple moving average of $4.38. Aclaris Therapeutics, Inc. has a one year low of $1.67 and a one year high of $6.51. The firm has a market capitalization of $819.35 million, a price-to-earnings ratio of -10.10 and a beta of 0.78.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.The firm had revenue of $1.63 million during the quarter, compared to analysts' expectations of $1.38 million. On average, sell-side analysts expect that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source